BeiGene Ltd. (BGNE)
| Market Cap | 30.97B |
| Revenue (ttm) | 265.67M |
| Net Income (ttm) | -1.51B |
| Shares Out | 1.15B |
| EPS (ttm) | -19.92 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | February 24 |
| Last Price | $334.90 |
| Previous Close | $332.47 |
| Change ($) | 2.43 |
| Change (%) | 0.73% |
| Day's Open | 326.68 |
| Day's Range | 322.25 - 339.89 |
| Day's Volume | 215,467 |
| 52-Week Range | 118.55 - 388.97 |
BOSTON & CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BTKi--Boston Immune Technologies and Therapeutics and BeiGene Enter into an Exclusive Option and License Agreement to Develop No...
The FDA has accepted for review BeiGene Ltd's (NASDAQ: BGNE) supplemental marketing application seeking approval for BRUKINSA (zanubrutinib) for the treatment of adult patients with Waldenströ...
CAMBRIDGE, Mass. & BEIJING, China--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene Announces U.S. FDA Acceptance of Supplemental New Drug Application for BRUKINSA (Zanubrutinib) in Waldenström's Macr...
Week In Review: Matridx Raises $32 Million For AI/CRISPR-Cas Pathogen Metagenomics Diagnostic Devices
CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)--BeiGene Announces Positive Topline Results for Global Phase 3 Trial of Tislelizumab in Esophageal Squamous Cell Carcinoma
HEMEL HEMPSTEAD, England & BEIJING, China & CAMBRIDGE, Mass.--(BUSINESS WIRE)--EUSA Pharma (UK) Limited and BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160) today announced that the Biologics License...
BeiGene out-licensed ex-China rights for tislelizumab, its China-approved anti-PD-1 antibody, to Novartis in a $2.2 billion agreement. Inmagene in-licensed global rights to four novel pre-clin...
BeiGene (BGNE) gains following the approval of tislelizumab for the lucrative indication of advanced squamous non-small cell lung cancer in China.
Beigene stock broke out and surged to a record high Thursday after China's regulators approved its lung cancer treatment. Earlier this week, Novartis signed on to commercialize the drug.
BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BGNE #BGNE--BeiGene's anti-PD-1 antibody received approval in China in first-line advanced squamous non-small cell lung cancer.
Novartis (NVS) in-licenses BeiGene's anti-PD-1 monoclonal antibody, tislelizumab, in major markets outside of China.
BeiGene (NASDAQ: BGNE) shares are trading higher after on Tuesday after the company announced a collaboration agreement with Novartis to developed and commercialize Anti-PD-1 antibody Tisleliz...
Beigene stock jumped Tuesday on a cancer drug development deal with Novartis worth up to $2.2 billion, as Vir Biotechnology also announced a hepatitis B tie-up with Gilead Sciences. The post B...
CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BGNE--BeiGene and Novartis enter into a collaboration to develop, manufacture and commercialize tislelizumab, BeiGene's anti-PD-1 antibody.
CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BGNE--Strand Therapeutics and BeiGene entered an option and license agreement aimed at developing, commercializing Strand's mRNA treatmen...
CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $bgne #beigene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing in...
BEIJING, China & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BGNE #BGNE--BeiGene announces inclusion of three innovative oncology products in China National Reimbursement Drug List (NRDL).
Trial Represents First-Ever Phase 0 for Newly Diagnosed Patients with Glioblastoma Trial Represents First-Ever Phase 0 for Newly Diagnosed Patients with Glioblastoma
BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BGNE #BGNE--BeiGene announces that BLINCYTO® (blinatumomab) for injection has been approved in China in relapsed/refractory B-cell precursor ALL.
CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #ASH20--BeiGene announces clinical data on BTK inhibitor BRUKINSA (zanubrutinib) in B-cell malignancies and Waldenström's at the 62nd ASH ...
CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #ASH20--BeiGene presents data on BTK inhibitor BRUKINSA in marginal zone lymphoma and chronic lymphocytic leukemia at the 62nd ASH Annual ...
CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BGNE--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innov...
CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BGNE--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innov...
CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $bgne #beigene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing in...
BeiGene is planning an IPO on the Shanghai Star Exchange that could raise up to $2.5 billion. BeiGene announced China approval to market Xgeva (denosumab) to prevent skeletal-related events (S...
BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BGNE #BGNE--BeiGene announces the second approval of XGEVA® (denosumab) in China.
Pharmaceuticals is the only sector that has all three characteristics foreign investors are looking for in Chinese investments: an industry that will consolidate, pro-growth policy reform and ...
CAMBRIDGE, Mass. & BEIJING, China--(BUSINESS WIRE)---- $BGNE #BGNE--Global Phase 3 trial of tislelizumab in second- or third-line non-small cell lung cancer met the primary endpoint at interim...
Innoforce, a Hangzhou company, formed a JV with Thermo Fisher Scientific to build a large biologics and steriles drug development and manufacturing facility in the Hangzhou Airport Economic De...
HEMEL HEMPSTEAD, England & BEIJING, China, & CAMBRIDGE, Mass.--(BUSINESS WIRE)--EUSA Pharma (UK) Limited and BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160) today announced that the Biologics Licens...
CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BGNE--BeiGene reports recent business highlights, anticipated upcoming milestones and financial results for the third quarter and first n...
CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #ASH--BeiGene announces data on BRUKINSA® (zanubrutinib) and tislelizumab to be presented at the 62nd ASH Annual Meeting.
SAN DIEGO & BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BGNE #BGNE--BeiGene will hold an exclusive license to the global clinical development and commercialization of BioAtla's investigat...
BeiGene, Ltd. (BGNE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.
Here we discuss four biotech stocks, which hold solid potential even amid the coronavirus crisis that continues unabated.
As of late, it has definitely been a great time to be an investor in BeiGene.
Want to invest in an industry that consistently outperforms the S&P 500? Here are three stocks to consider.
CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BGNE--BeiGene presents Phase 3 data of tislelizumab in non-squamous non-small cell lung cancer and Phase 2 data of pamiparib in ovarian c...
CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $bgne #beigene--BeiGene announced that the Company will present at the Morgan Stanley 18th Annual Global Healthcare Conference on Thurs, Sept 17...
CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BGNE--Health Canada accepted BeiGene's New Drug Submission for BRUKINSA® (zanubrutinib) in Waldenström’s macroglobulinemia (WM) and grant...
BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BGNE #BGNE--BeiGene announces inclusion in Shanghai-Hong Kong Stock Connect and inclusion in Hang Seng Composite Index (HSCI).
BeiGene COVID-19 Deal And Other News: The Good, Bad And Ugly Of Biopharma
BEIJING, China & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BGNE #BGNE--BeiGene and Singlomics enter an exclusive license agreement for Singlomics’ investigational anti-COVID-19 antibodies, includ...
CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BGNE--BeiGene appoints Corsee Sanders, Ph.D.
GUANGZHOU & BEIJING & CAMBRIDGE, Mass--(BUSINESS WIRE)---- $BGNE--Bio-Thera Solutions and BeiGene announce license, distribution, and supply agreement for Avastin® (bevacizumab) biosimilar BAT...
BeiGene, Ltd. (BGNE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
CAMBRIDGE, Mass. and BEIJING, China, Aug. 06, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercia...
CAMBRIDGE, Mass. and BEIJING, China, Aug. 05, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercia...
BEIJING, China and CAMBRIDGE, Mass., July 27, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company, today announced that the Center fo...
More than 100% stock gain without posting an operating profit - that’s what Autodesk, Alnylam Pharma, BeiGene, Chegg, and Coupa Software have done over the past three years! This counter-intui...
About BGNE
BeiGene,, a commercial-stage biotechnology company, develops and commercializes molecularly-targeted and immuno-oncology cancer therapeutics in the People's Republic of China, the United States, and internationally. Its commercial products include BRUKINSA to treat R/R mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; ABRAXANE to treat breast cancer; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumo... [Read more...]
| Industry Biotechnology | IPO Date Feb 3, 2016 |
| CEO John Oyler | Employees 4,600 |
| Stock Exchange NASDAQ | Ticker Symbol BGNE |
Financial Performance
In 2019, BeiGene's revenue was $428.21 million, an increase of 116.03% compared to the previous year's $198.22 million. Losses were -$948.63 million, 40.8% more than in 2018.
Analyst Forecasts
According to 19 analysts, the average rating for BeiGene stock is "Buy." The 12-month stock price forecast is 314.02, which is a decrease of -6.23% from the latest price.